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Abstract
Background and aim: Given their poor prognosis, patients with residual disease (RD) in the re-resection specimen
of an incidental gallbladder carcinoma (IGBC) could benefit from a better selection for surgical treatment. The
Gallbladder Cancer Risk Score (GBRS) has been proposed to preoperatively identify RD risk more precisely than T-
stage alone. The aim of this study was to assess the prognostic value of RD and to validate the GBRS in a
retrospective series of patients.
Material and methods: A prospectively collected database including 59 patients with IGBC diagnosed from
December 1996 to November 2015 was retrospectively analyzed. Three locations of RD were established: local,
regional, and distant. The effect of RD on overall survival (OS) was analyzed with the Kaplan-Meier method.
To identify variables associated with the presence of RD, characteristics of patients with and without RD were
compared using Fisher’s exact test. The relative risk of RD associated with clinical and pathologic factors was
studied with a univariate logistic regression analysis.
Results: RD was found in 30 patients (50.8%). The presence of RD in any location was associated with worse
OS (29% vs. 74.2%, p = 0.0001), even after an R0 resection (37.7% vs 74.2%, p = 0.003). There was no significant
difference in survival between patients without RD and with local RD (74.2% vs 64.3%, p = 0.266), nor between patients
with regional RD and distant RD (16.1% vs 20%, p = 0.411). After selecting patients in which R0 resection was achieved
(n = 44), 5-year survival rate for patients without RD, local RD, and regional RD was, respectively, 74.2%, 75%, and 13.9%
(p = 0.0001). The GBRS could be calculated in 25 cases (42.3%), and its usefulness to predict the presence of regional or
distant RD (RDRD) was confirmed (80% in high-risk patients and 30% in intermediate risk p = 0.041).
Conclusion: RDRD, but not local RD, represents a negative prognostic factor of OS. The GBRS was useful to
preoperatively identify patients with high risk of RDRD. An R0 resection did not improve OS of patients with
regional RD.
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Background
Since the widespread adoption of the laparoscopic ap-
proach, the number of patients diagnosed with incidental
gallbladder carcinoma (IGBC) has increased. Although
there is some controversy, the most common definition of
IGBC is a histologic diagnosis of malignancy after an
elective cholecystectomy for presumed benign disease.
This is the definition used in the present study.
Re-resection of patients with IGBC is recommended in
T1b, T2, and T3 tumors without disseminated disease.
The main goal of the reoperation is to resect the pos-
sible residual disease (RD), in order to improve patient’s
survival and to perform a correct staging [1–8].
The prognostic value of RD has received much attention
in recent years [3–5, 7–11] and it has been suggested that
surgery does not improve survival of patients with RD
[11–13]. Patients with known or high risk of RD might
benefit from a specific strategy that could include an ex-
tended staging study, a longer observation period before
re-resection, the administration of preoperative chemo-
therapy (CHT), and an exploratory laparoscopy before the
reoperation [7]. This strategy could improve patient selec-
tion prior to attempt re-resection.
Given the limitations of imaging studies for preoperative
staging [12, 14, 15], attempts have been made to predict
RD risk from the pathological data of the cholecystectomy
specimen. In this sense, the Gallbladder Cancer Predictive
Risk Score (GBRS) [16] has been proposed but not yet val-
idated. The aim of the present study was to assess the
prognostic value of RD and to validate the GBRS in a
retrospective series of patients with IGBC.
Patients and method
The Gallbladder Cancer Predictive Risk Score (GBRS)
published in 2016 [16] was developed using T-stage,
tumor grade, presence of lymphovascular invasion (LVI)
and perineural invasion (PNI) determined in the chole-
cystectomy specimen. Each factor was assigned a value
which was added to obtain a total risk score ranging
from 3 to 10. The scores were then separated into three
risk groups: low (3–4), intermediate (5–7), and high (8–
10). The primary endpoint of the authors was to assess
the predictive value of the GBRS in finding loco-regional
or distant RD at the time of re-resection for IGBC.
From December 1996 to November 2015, data from
60 consecutive patients diagnosed with IGBC who
underwent a re-resection was obtained from a prospect-
ively maintained database. Before the reoperation, patients
underwent a physical examination, and blood samples
were obtained. Imaging techniques included an enhanced
thoraco-abdominal CT scan in all cases and, since 2010, a
PET/CT FDG scan and an MRI. Reports and histological
preparations of cholecystectomy specimen performed in
outside hospitals were reviewed by an expert pathologist
from our center. Radical resection was recommended in
all patients who presented stage T1b or higher, or cystic
margin invasion without evidence of disseminated disease.
Surgery consisted of a resection of the vesicular bed or
an anatomical resection of liver segments IVb/V. A
lymphadenectomy of the hepatic hilum was associated in
all cases. Bile duct resection was carried out in patients
with cystic margin involvement and in two patients in
whom common bile duct ischemia after lymphadenec-
tomy was suspected.
Surgical excision of the port sites was only carried out
in selected cases. Postoperative mortality was defined by
death within the first 90 days after surgery.
The presence of RD was established by the pathology
findings in intraoperative samples or in the resected speci-
men. Three locations of RD were established: (1) local,
when isolated non-discontinuous involvement of the ves-
icular bed or the cystic stump was found; (2) regional,
which included common bile duct involvement, PNI, LVI,
lymph node invasion, or invasion of neighboring organs;
and (3) distant, when discontinuous hepatic involvement
(metastasis) or peritoneal carcinomatosis were present.
Staging after re-resection was obtained with data from
both surgeries according to the 7th edition of the TNM
classification of the American Joint Committee on Cancer
(AJCC). Follow-up included a physical examination, blood
tests, and a thoraco-abdominal CT scan every 6months.
Recurrences were confirmed by histologic or radiological
findings. Patients’ data were anonymized, and the study
protocol was approved by the Bellvitge University Hospital’s
Clinical Research Ethic Committee (PR072/18).
Statistical analysis
Results are presented as proportions for qualitative vari-
ables and as mean and standard deviation for continuous
variables. Survival was calculated from the reoperation
date until death or end of follow-up.
In order to determine the prognostic value of RD on
OS, survival curves were constructed using the Kaplan-
Meier method and compared with the log-rank test. To
identify variables associated with the presence of RD, the
characteristics of patients with and without RD were
compared using the Fisher’s exact test. Statistical signifi-
cance was considered when p < 0.05. To assess the
relative risk (RR) of RD associated with clinical and
pathologic factors, univariate logistic regression analysis
was performed.
As the tumor was usually diagnosed at outside institu-
tions, potentially relevant pathology information was
missing for many patients. To determine if the samples
with incomplete information were biased, the analysis of
prognostic factors included unknown as a separate cat-
egory. Analysis was performed using IBM SPSS Statistics
25.0 (IBM Ins, Armonk, NY).
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Results
A patient with Tis stage in the cholecystectomy speci-
men was excluded from the study due to a diffuse in-
volvement of the entire biliary tract epithelium identified
in the reoperation. The demographic characteristics of
the remaining 59 patients and the pathology findings of
the cholecystectomy specimen are presented in Table 1.
No patient received preoperative chemotherapy. RD was
found in 30 patients (50.8%). Distant (n = 9) or extensive
regional disease (n = 1), not detected in preoperative
staging, was found in 10 patients at reoperation and thus
resection was performed in 49 patients (44 R0 and 5
R1). No patient died in the postoperative period.
The characteristics of our patients are compared with
those of Ethun et al. [16] in Table 1. The latter have a
greater proportion of unknown data, a more advanced
Table 1 Demographic characteristics of the complete series, pathologic data from the cholecystectomy specimen, and operative
data at re-resection. Comparison with the Ethun et al. series [16]
Ramos et al., n = 59 Ethun et al., n = 262 P (unknown excluded)




Surgical approach, open or converted/laparoscopic 19/40
T-stage, n (%) Unknown – 36 (13.7) < 0.001
T(1a + 1b) 5 (8.5) 22 (8.3)
T2 46 (78) 113 (43)
T3/T4 8 (13.6) 91 (34.7)
N, N0/N1/unknown 11/15/33
Affected cystic margin, Y/N/unknown 16/30/13
Grade of differentiation n (%) Unknown 17 (29) 67 (25.5) 0.040
Well 11 (18.3) 24 (9.1)
Moderately 24 (40) 115 43.8)
Poorly 7 (11.7) 56 (21.3)
Histology, adenocarcinoma/other 48/11
Lymphovascular invasion, n (%) Unknown 12 (20.3) 149 (57) 0.136
No 32 (54.2) 61 (23.2)
Yes 15 (5.4) 52 (19.8)
Perineural invasion, n (%) Unknown 24 (40.7) 145 (55.3)
No 19 (32.2) 55 (21) 0.369
Yes 16 (27.1) 62 (23.6)
GBRS Unknown 34/59 174/262
High 5 (20) 42 (48) 0.030
Intermediate 20 (80) 42 (48)
Low 0 4 (4)
Time to reoperation (weeks), mean (SD) 12.4 (6.2) 9.3 (14.3) 0.010
Completed re-resection, n (%) 49 (83) 214 (82) 0.804
Liver resection, n (%) 46/49 (94) 191 (89) 0.327
Common bile duct resection, n (%) 23/49 (47) 73 (34) 0.092
Port-site excision, n (%) 16/49 (32) 87 (40) 0.677
Final margin status R0, n (%) 44 (74.5) 196 (75) 0.974
RD at reoperation, n (%) 30 (50.8) 174 (66.4) 0.05
Local or regional 21 (35.5) 129 (49.2)
Distant 9 (15.3) 45 (17.2)
Final TNM staging, 7th ed. 0,I/II/IIIa,IIIb,IV 5/22/32
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tumor stage, and a higher incidence of RD. No differ-
ences were seen in aspects related to the surgical
technique, except for the time interval between both
operations, which was longer in our series.
Prognostic value of RD and influence of its anatomical
location
Patients with confirmed RD at reoperation had a lower
5-year survival rate than patients without RD (29% vs.
74.2%, p = 0.0001) even after an R0 resection (37.7% vs
74.2%, p = 0.003).
The 5-year survival rate of patients with local RD, re-
gional RD, and distant RD was 64.3%, 16.1%, and 20%, re-
spectively. Patients without RD and patients with local RD
had similar 5-year survival rate (p = 0.266). The 5-year
survival rate of patients with regional RD was similar to
that of patients with distant RD (p = 0.411).
After selecting patients in which R0 resection was achieved
(n = 44), 5-year survival rate for patients without RD (n=
29), with local RD (n= 6), and with regional RD (n= 9) was,
respectively, 74.2%, 75%, and 13.9% (p= 0.0001) (Fig. 1).
Predictive factors of regional and/or distant RD
Given that the survival of patients with local RD was
similar to that of patients without RD, an analysis was
performed to identify the predictive variables of regional
and/or distant RD (RDRD) whose presence was associ-
ated with lower survival. In the univariate logistic regres-
sion analysis, T-stage, LVI, and PNI showed a
statistically significant association with the presence of
RDRD (Table 2).
The GBRS could be calculated in 25 patients
(42.3%). No significant differences for any of the clin-
ical, pathological, and operative variables included in
Table 1, were observed compared with the rest of the
patients included in the study thus ruling out a sys-
tematic bias.
In the group of patients with complete data available,
the GBRS was the only predictive variable predictive of
RDRD (p = 0.041) (Table 3). Values ranged from 5 to 9
(mean 6.48 ± 1.29). Twenty cases were in the intermedi-
ate risk category and only five in the high-risk category.
The incidence of RDRD was 30% in patients with inter-
mediate risk, and 80% in the high-risk category (p =
0.041). T2 stage patients represented the largest sub-
group (n = 21), 17 belonged to the intermediate category
and 4 to the high risk. The incidence of RDRD was
29.4% and 75% (p = 0.091), respectively. Three of the
four T2 high-risk patients presented distant RD, com-
pared to none in the intermediate risk group.
Fig. 1 Long-term survival after an R0 resection (n = 44) for patients without RD (n = 29), with local RD (n = 6) and with regional RD (n = 9)
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Discussion
Several studies have shown that RD represents a negative
prognostic factor for survival after re-resection of IGBC
[3, 7, 12, 16]. Results observed in our series are similar,
but contrary to other published experiences, the prognostic
value of RD depended on its anatomical situation.
Patients with local RD showed a 5-year survival rate
similar to that of patients without RD (Fig. 1). In other
studies [5, 10, 12, 17], local RD was associated with
worse survival. This divergence in results could be due
to the way in which liver involvement is classified (local
extension of the tumor not excised in the first surgery vs
metastatic disease). Continuity of the tumor with the
gallbladder bed was observed in all our patients with
isolated hepatic RD treated with an R0 resection. It was
therefore a true local disease.
Table 2 Analysis of predictive factors of regional and/or distant RD (RDRD). Fisher’s exact test and univariate logistic regression.
Patients with unknown data had no significant differences regarding the risk of RDRD, compared to patients in the reference
categories. This rules out bias due to missing values
% Regional and/or distant residual disease P RR (CI 95%) P
Cholecystectomy 0.975 0.975
Urgent 7/16 (43) 1.02 (0.37–3.38)
Elective 17/43 (39.5) REF
Surgical approach 0.138 0.142
Open or converted 10/19 (52.6) 2.03 (0.755–7.05)
Laparoscopic 13/40 (32.5) REF
Cystic margin invasion 0.658 0.660
Yes 7/16 (43.8) 1.10 (0.25–4.79)
Unknown 6/13 (46.2) 0.64 (0.18–2.23)
No 10/30 (33.3) REF
T-stage 0.003 0.021
T3 7/8 (87.5) 13.12 (1.48–116.26)
T2 16/46 (34.8) REF
Tis + T1a + T1b 0/5 (0) –
Positive lymph nodes 0.412 0.420
N+ 8/15 (53.3) 2.00 (0.40–9.83)
Unknown 11/33 (33.3) 0.87 (0.21–3.64)
N0 4/15 (36.4) REF
Grade 0.691 0.698
Poorly 2/7 (28.6) 1.06 (0.12–8.79)
Moderately 11/24 (45.8) 2.25 (0.47–10.64)
Unknown 7/17 (41.2) 1.86 (0.36–9.63)
Well 3/11 (27.3) REF
Histology 0.241 0.247
Other 6/11 (54.5) 2.18 (0.58–8.24)
Adenocarcinoma 17/38 (35.4) REF
Lymphovascular invasion 0.005 0.010
Yes 11/15 (73.3) 6.05 (1.54–23.73)
Unknown 2/12 (16.7) 0.44 (0.81–2.39)
No 10/32 (31.3) REF
Perineural invasion 0.016 0.024
Yes 11/16 (68.8) 6.16 (1.41–26.75)
Unknown 7/24 (29.2) 1.15 (0.29–4.3)
No 5/19 (26.3) REF
Significant data are in bold
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It has been suggested that the worsening of the prog-
nosis related to RD could be due to disruption of the
natural barriers between the tumor and the lymphatic
network in the gallbladder bed or in the serosa layer, or
to an intraoperative gallbladder perforation [18, 19].
The literature has highlighted the need to achieve an
R0 resection with the aim of improving the prognosis of
patients with IGBC [1, 4, 20]. However, in our study, the
survival of patients with regional RD was similar to that
of patients with distant RD, even after an R0 resection.
The favorable results of the R0 resections observed in
some publications are probably due to the inclusion in
the analysis of patients without RD. This observation
may support the administration of preoperative chemo-
therapy to patients with suspected regional RD. Unfortu-
nately, imaging tests are not very reliable for the
preoperative detection of RD. This could be explained
by the small size of the tumoral disease that in many
cases may be microscopic. It has been suggested that
delaying preoperative staging up to 3 months after chole-
cystectomy may improve their results [15].
Given the limitations of radiological staging, attempts
have been made to establish the risk of RD from histo-
logical findings in the cholecystectomy specimen [7, 16].
Similar to other studies [1–3, 7, 8, 12], T-stage in our
series was a significant prognostic factor of RD. The
prognostic value of other histological variables is difficult
to assess due to the high proportion of missing data in
most published series [7, 12, 16, 21].
In our series, besides T-stage, LVI and PNI were pre-
dictive factors of RDRD (Table 2). Together with the
grade of differentiation, these are the factors used by
Ethun et al. to develop the GBRS. The lack of signifi-
cance of grade of differentiation in our study could be
explained by the low proportion of patients with poorly
differentiated tumors (12%). The incidence was 21% in
the Ethun et al. study [16] and 40% in Creasy’s [7].
These data suggest relevant differences in patients’ char-
acteristics among published series, which along with the
problem of missing data can make it more difficult to
obtain a useful score.
The GBRS could be calculated in 25 of the 59 patients
(42.3%) and in this subgroup was the only predictive
variable of RDRD (Table 3). The incidence of RDRD was
significantly higher in high-risk patients than in
intermediate-risk patients (80% vs 30%, p = 0.041). In
T2-stage patients, the GBRS distinguished two groups
with a difference in the incidence of RDRD, close to stat-
istical significance (75% vs. 29.4%, p = 0.091). This obser-
vation may be especially relevant for clinical practice,
since T2-stage [22] is the most frequent.
The recent reviews published by Søreide et al. [23]
and Cherkassy et al. [24] emphasize the importance
of tumor biology in the prognosis of patients with
IGBC, as well as the need to select the patients who
will undergo re-resection. In addition Cherkassky
et al. propose a chemotherapy first approach in pa-
tients at high risk of micrometastatic disease. There-
fore patients classified as high risk of RDRD by the
GBRS could be eligible for this approach. In our
series, three of the four T2-stage high-risk patients
presented distant RD. However, this strategy should
be indicated selectively, due to the risk of local pro-
gression or deterioration of functional status that
could ultimately prevent re-resection.
Like other malignancies IGBC is a heterogeneous dis-
ease with various clinical and pathological presentations
[25, 26]. In this scenario, a multiparameter score like
GBRS could be a useful tool to complete a better prog-
nostic assessment.
The present study has some obvious limitations due
to its retrospective nature and the percentage of in-
complete pathology data in the cholecystectomy speci-
men. However, data was prospectively collected and
because of the statistical methodology used, it does
not seem likely that the missing data could have in-
troduced a significant bias in the results. However,
given the sample size, the results should be consid-
ered with caution while waiting for new prospective
studies to confirm the conclusions.
Table 3 Analysis of predictive histological factors of regional
and/or distant residual disease (RDRD) in the 25 patients in






















Significant data are in bold
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Conclusions
Regional RD, but not local RD, in patients with IGBC
constitutes a significant poor prognostic factor, even after
an R0 resection. In our study, GBRS has been shown to be
effective in identifying patients at high risk of RDRD.
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